A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 5, Issue 5, 2008, Pages 278-281

  Quin, Alissa ^a   Kane, Sunanda ^b   Ulitsky, Olga ^c  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b Mayo Clinic College of Medicine   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMOXICILLIN; ANTIBIOTIC AGENT; CLAVULANIC ACID; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; THALIDOMIDE;

ADULT; ANUS FISTULA; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLITIS; CROHN DISEASE; DISEASE DURATION; DRUG DOSE INCREASE; ERYTHEMA NODOSUM; FEMALE; FEVER; FOLLOW UP; GASTROENTEROLOGY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; ILEOSTOMY; INTERSTITIAL PNEUMONIA; LABORATORY TEST; MEDICAL SPECIALIST; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROCTOCOLECTOMY; RECTOSCOPY; RECTUM DISEASE; SKIN BIOPSY; SWELLING;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; ERYTHEMA NODOSUM; FEMALE; HUMANS; INTESTINAL FISTULA; TREATMENT OUTCOME;

EID: 43149084554     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep1099     Document Type: Article

References (15)

1. Requena L and Sánchez YE (2007) Erythema nodosum. Semin Cutan Med Surg 26: 114-125
2. Schwartz R and Nervi S (2007) Erythema nodosum: A sign of systemic disease. Am Fam Physician 75: 695-700
3. Trost L and McDonnell JK (2005) Important cutaneous manifestation of inflammatory bowel disease. Postgrad Med J 81: 580-585
4. Weinstein M et al. (2005) Erythema nodosum as a presentation of inflammatory bowel disease. Can Med Assoc J 173: 145-146
5. Tavarela Veloso F (2004) Review article: Skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther 20 (Suppl 4): 50-53
6. Kethu SR (2006) Extraintestinal manifestations of inflammatory bowel diseases. J Clin Gastroenterol 40: 467-475
7. Nguyen GC (2006) Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: Characterization of a large North American cohort. Am J Gastroenterol 101: 1012-1023
8. Barrie A and Plevy S (2006) Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease within infliximab. Gastroenterol Clin North Am 35: 883-893
9. Graves JE et al. (2007) Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 56 e55-79
10. Papadakis KA et al. (2005) Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 100: 75-79
11. Sandborn W et al. (2004) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99: 1984-1989
12. Hanauer SB et al. (2006) Human anti-tumor necrosis factor monoclonal antibody. (Adalimumab) in Crohn's disease: The CLASSIC-I Trial. Gastroenterology 130: 323-333
13. Vesga L et al. (2005) Adalimumab use in pregnancy. Gut 54 890
14. Ortego-Centeno N et al. (2007) Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dematol Venereol 21: 409-410
15. Fonder MA et al. (2006) Adalimumab therapy for recalcitrant pyoderma gangrenosum: JEBurns Wounds 5: e8